Uttar Pradesh

Opportunity for M.Pharm, M.Sc, B.Pharm to work in areas of Pharmacognosy/Pharmacology and Tissue culture & Transformation @ CSIR-NBRI

NBRI is a premier plant based multidisciplinary, state-of-art national R&D Centre of CSIR undertaking research from classical taxonomy to cutting edge areas of modern biology-including both applied and basic research in the fields of biochemistry, bioinformatics, biotechnology, conservation biology, cytogenetics, environmental sciences, ethnopharmacology, floriculture, microbiology, molecular biology and genetic engineering, pharmacognosy

Work as Full Time and Part Time - Clinical Trial Operations, CDM, Pharmacovigilance, Medical Writing in Clini India

Clini India is a progressive and premier academy in clinical research that has rapidly gaining a good reputation for excellence through its innovative approach in clinical research. Clini India is an academy with a good reputation in clinical research industry. Clini India is a premier institution of CR education in clinical research domain. Clini India delivers Full time, Part time and e- learning training in Clinical research education.

CDRI invites online applications from M.Pharm/M.Sc for engagement of Project Staff under different projects - 7 Posts

CSIR-Central Drug Research Institute, Lucknow is a premier R&D Institute under the aegis of the Council of Scientific and Industrial Research (CSIR), New Delhi which is an autonomous body under Department of Scientific and Industrial Research, Government of India.

TAK-875- A NEWER NOVEL ORAL TREATMENT FOR TYPE-2 DIABETES: A REVIEW

About Authors:
Satyanand tyagi*, Raghvendra1
*President, Tyagi Pharmacy Association & Scientific Writer,
Chattarpur, New Delhi, India-110074.
Prof. Satyanand Tyagi is a life time member of various pharmacy professional bodies like IPA, APTI and IPGA. He has published various research papers and review articles. His academic works include 45 Publications (37 Review Articles and 08 Research Articles of Pharmaceutical, Medicinal and Clinical Importance, published in standard and reputed National and International Pharmacy journals; Out of 45 publications, 10 are International Publications).
1Department of Pharmaceutics, Aligarh College of Pharmacy,
Aligarh, U.P, India-202001.
*sntyagi9@yahoo.com,
+91-9871111375 / 9582025220

ABSTRACT
Tak-875, a new treatment for type-2 diabetes, improves blood sugar control and is equally effective as glimepiride (Sulfonylurea, oral hypoglycaemic agent), but has a significantly lower risk of hypoglycaemia, according to a new study. It works by boosting the release of insulin from pancreatic beta cells when glucose and fatty acids rise in the blood, such as after a meal, which results in a fall in blood glucose levels. TAK-875 is a novel oral medication designed to enhance insulin secretion in a glucose dependent manner, which means that it has no effect on insulin secretion when glucose levels are normal, and as such has the potential to improve the control of blood sugar levels without the risk of hypoglycaemia. The pill belongs to a new class of treatments called GPR40 agonists, which activate a receptor that stimulates and regulates insulin production. New treatments are needed because of “the expected increase in the number of cases of Type 2 diabetes during the next few decades” and because some current drugs have “insufficient effect,” the researchers, led by Charles Burant at the University of Michigan Medical School, wrote in the study. Free fatty acid receptor 1 (FFA1), also known as G protein-coupled receptor 40 (GPR40), plays a vital role in stimulating and regulating the production of insulin. It works by boosting the release of insulin from pancreatic β-cells when glucose and fatty acids rise in the blood, such as after a meal. The release of insulin results in a fall in blood glucose levels. Drugs that activate the FFAR1 receptor have the potential to help diabetics release more insulin and improve control of blood glucose levels. This article gives an overview about this newly introduced drug TAK-875 and its role in treatment for type-2 diabetes.

Opportunity for Senior Research Fellow in CCRH - 2 Posts | Pharmacognosy/Botany, Chemistry

The Central Council for Research in Homoeopathy (CCRH), New Delhi, an autonomous body of Department of AYUSH, Ministry of Health & Family Welfare, Govt. of India intends to engage the following categories of personnel. The persons selected will be liable for posting in its peripherals Institutes/Units located through out the country. The engagement will be purely on contract basis and selection will be made through Walk-in-Interview:

VARIOUS PREPARATION TECHNIQUE OF POLYMERIC NANOPARTICLE

About Authors:
*Avanish kumar dubey, Amit singh
R.V. Northland Institute dadri,
G.B. Nagar UP
*avpharma001@gmail.com

Abstract
Polymer nanoparticles have attracted the interest of researcher and have been utilized the increasing number of field. Generally two main strategies are employed for the preparation of polymeric nanoparticles. either polymerization of monomers or the dispersion of pre-form polymers. Various techniques can be used to produce polymeric nanoparticles such as salting out method, double  desolvation method, ionic gelation method, cross linked nanoparticles, nanoparticle by super critical fluid, emulsification and solvent evaporation method. The choice of method depends on a number of factor such as particle size, particle size distribution, area of application, nature of polymer etc. This review cover the general description on various methods of the preparation of polymeric nanoparticle.

Pages